Search Results - "Lichter, Peter"

Refine Results
  1. 1

    Chromothripsis in cancer cells: An update by Rode, Agata, Maass, Kendra Korinna, Willmund, Karolin Viktoria, Lichter, Peter, Ernst, Aurélie

    Published in International journal of cancer (15-05-2016)
    “…In 2011, a novel form of genome instability was reported by Stephens et al., characterized by tens to hundreds of locally clustered rearrangements affecting…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4

    Time-resolved, integrated analysis of clonally evolving genomes by Legrand, Carine, Andriantsoa, Ranja, Lichter, Peter, Raddatz, Günter, Lyko, Frank

    Published in PLoS genetics (01-12-2023)
    “…Clonal genome evolution is a key feature of asexually reproducing species and human cancer development. While many studies have described the landscapes of…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9

    miRNA-130a Targets ATG2B and DICER1 to Inhibit Autophagy and Trigger Killing of Chronic Lymphocytic Leukemia Cells by KOVALEVA, Valentina, MORA, Rodrigo, SEIFFERT, Martina, YOON JUNG PARK, PLASS, Christoph, CHIRAMEL, Abhilash I, BARTENSCHLAGER, Ralf, DÖHNER, Hartmut, STILGENBAUER, Stephan, PSCHERER, Armin, LICHTER, Peter

    Published in Cancer research (Chicago, Ill.) (01-04-2012)
    “…Toxicity and relapses from the immunochemotherapy used to treat chronic lymphocytic leukemia (CLL) prompt continued interest in gentle but effective targeted…”
    Get full text
    Journal Article
  10. 10

    Elastic SCAD as a novel penalization method for SVM classification tasks in high-dimensional data by Becker, Natalia, Toedt, Grischa, Lichter, Peter, Benner, Axel

    Published in BMC bioinformatics (09-05-2011)
    “…Classification and variable selection play an important role in knowledge discovery in high-dimensional data. Although Support Vector Machine (SVM) algorithms…”
    Get full text
    Journal Article
  11. 11
  12. 12

    MAPK pathway activation in pilocytic astrocytoma by Jones, David T. W., Gronych, Jan, Lichter, Peter, Witt, Olaf, Pfister, Stefan M.

    “…Pilocytic astrocytoma (PA) is the most common tumor of the pediatric central nervous system (CNS). A body of research over recent years has demonstrated a key…”
    Get full text
    Journal Article
  13. 13

    Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients by ZEPPERNICK, Felix, AHMADI, Rezvan, CAMPOS, Benito, DICTUS, Christine, HELMKE, Burkhard M, BECKER, Natalia, LICHTER, Peter, UNTERBERG, Andreas, RADLWIMMER, Bernhard, HEROLD-MENDE, Christel C

    Published in Clinical cancer research (01-01-2008)
    “…Purpose: The CD133 antigen has been identified as a putative stem cell marker in normal and malignant brain tissues. In gliomas, it is used to enrich a…”
    Get full text
    Journal Article
  14. 14
  15. 15

    Macromolecular crowding and its potential impact on nuclear function by Richter, Karsten, Nessling, Michelle, Lichter, Peter

    Published in Biochimica et biophysica acta (01-11-2008)
    “…It is well established, that biochemical reactions are dependent on pH, ionic strength, temperature and the concentration of reactants. However, the steric…”
    Get full text
    Journal Article
  16. 16

    The need for a worldwide consensus for cell line authentication: Experience implementing a mandatory requirement at the International Journal of Cancer by Fusenig, Norbert E, Capes-Davis, Amanda, Bianchini, Franca, Sundell, Sherryl, Lichter, Peter

    Published in PLoS biology (17-04-2017)
    “…Cell lines are used in life science research worldwide as biological surrogates. All cell lines are subject to major limitations when used as research tools,…”
    Get full text
    Journal Article
  17. 17
  18. 18
  19. 19
  20. 20

    Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice by Hanna, Bola S, Yazdanparast, Haniyeh, Demerdash, Yasmin, Roessner, Philipp M, Schulz, Ralph, Lichter, Peter, Stilgenbauer, Stephan, Seiffert, Martina

    Published in Haematologica (Roma) (01-04-2021)
    “…Ibrutinib is a bruton's tyrosine kinase (BTK) inhibitor approved for the treatment of multiple B-cell malignancies, including chronic lymphocytic leukemia…”
    Get full text
    Journal Article